10-Q · May 13, 2026
Abeona Therapeutics reported Q1 2026 results with net product revenue of $8.72 million, a stark increase from zero revenue in Q1 2025 due to the FDA approval of ZEVASKYN®. While the net loss widened to $(17.1) million…
Earnings analysis · 10-Q
ABEO earnings analysis
Filed August 13, 2026 · Our reading of the company's report
The latest report
Abeona’s commercial ramp continued, with revenue of $11.380 million, approximately 26% above the prior quarter, and ZEVASKYN revenue up 31% sequentially. However, diluted EPS declined to $(0.35) from $(0.30), revenue…
Read full summary
Abeona’s commercial ramp continued, with revenue of $11.380 million, approximately 26% above the prior quarter, and ZEVASKYN revenue up 31% sequentially. However, diluted EPS declined to $(0.35) from $(0.30), revenue missed the $12.342 million consensus estimate, and cash was $146.8 million against approximately negative $22 million of quarterly free cash flow. The principal adverse development is continuing manufacturing and release-test uncertainty, including a July 2026 batch that could not be released as commercial product; no quantitative forward guidance was provided.
Reported figures
- Earnings per share
- $-0.35
- Segment
- ZEVASKYN: $11.380 million of revenue, up 31% sequentially; no other reportable segment revenue disclosed
What stood out
-
ZEVASKYN revenue continued to expand
Revenue was $11.380 million, up approximately 26% from $9.0 million in the prior quarter and substantially above $0.4 million in the year-ago quarter. ZEVASKYN revenue increased 31% sequentially to $11.380 million.
-
Commercial revenue ramp continued
The company reported $11.380 million of quarterly revenue, but diluted EPS was $(0.35), compared with $(0.30) in 2026 Q1, indicating sequentially wider per-share losses.
-
No material control deficiencies reported
Disclosure controls were concluded effective as of June 30, 2026, and the company reported no changes in internal control over financial reporting that materially affected, or were reasonably likely to materially affect, controls during the quarter.
-
No new legal or insider-trading issues
The filing reports no legal proceedings and states that none of the company’s directors or officers adopted, modified, or terminated a Rule 10b5-1 or non-Rule 10b5-1 trading arrangement during the three months ended June 30, 2026.
What to watch
-
Commercial manufacturing remains constrained
A ZEVASKYN batch manufactured after a July 2026 patient biopsy could not be released as commercial product because a cellular identity test was out of specification. The FDA authorized release only under a single-patient IND, and the company cannot guarantee acceptance of its proposed specification revision.
-
Release-test failures threaten supply
The filing identifies at least 2 material manufacturing-release events: a batch following an August 2025 biopsy was rejected after a false-positive sterility result, and a batch following a July 2026 biopsy failed a cellular identity specification. Such issues could adversely affect cash flow and results.
-
Cash burn remains substantial
The company reported $146.8 million of cash while quarterly free cash flow was approximately negative $22 million, indicating continued liquidity consumption as commercialization scales.
Management's outlook
No formal quantitative revenue or EPS guidance was provided in the filing; outlook was deferred to the earnings release or call.
Earlier filings 1
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.